Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Acquisitions & Divestments (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $179.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 12.73% to $179.8 million in Q4 2025 year-over-year; TTM through Nov 2025 was $617.5 million, a 34.39% increase, with the full-year FY2025 number at $617.5 million, up 34.39% from a year prior.
  • Change in Acquisitions & Divestments was $179.8 million for Q4 2025 at Nurix Therapeutics, up from $156.2 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $179.8 million in Q4 2025 to a low of $41.0 million in Q1 2023.
  • A 5-year average of $95.9 million and a median of $88.8 million in 2022 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 1180.08% in 2021, then tumbled 30.23% in 2023.
  • Nurix Therapeutics' Change in Acquisitions & Divestments stood at $55.0 million in 2021, then surged by 53.54% to $84.5 million in 2022, then decreased by 9.33% to $76.6 million in 2023, then skyrocketed by 108.21% to $159.5 million in 2024, then grew by 12.73% to $179.8 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Change in Acquisitions & Divestments are $179.8 million (Q4 2025), $156.2 million (Q3 2025), and $142.3 million (Q2 2025).